Polypeptides inhibiting neovascularization and uses thereof

a neovascularization and polypeptide technology, applied in the field of biomedicine, can solve the problems of many anatomical and functional barriers in eyes, unsatisfactory long-term efficacy, and destruction of local tissues, and achieve the effects of inhibiting the proliferation of huvecs, inhibiting the formation of lumens, and inhibiting endothelial cell proliferation

Inactive Publication Date: 2015-04-23
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012]The purpose of the present invention is to provide a small molecular polypeptide, and the fragments, analogs, and derivatives thereof, which are suitable for eyeball tissue, effective and safe for inhibit angiogenesis.

Problems solved by technology

However, these treatments tend to destroy local tissues, and the long-term efficacy thereof is still unsatisfactory.
Firstly, there are many anatomical and functional barriers in eyes.
Systemic administration usually cannot result in a topically sufficient drug concentration in ocular tissue due to the blood-aqueous humor barrier and blood-retina barrier.
Theoretically, in topical administration, such as injection in vitreous cavity, it is difficult for any macromolecule larger than 76.5 kDa to penetrate the retina and act on the retinal and choroidal angiogenesis.
Thirdly, for the above major reasons, the bioavailability of ocular drugs is very low.
However, compounds for treating neoplastic angiogenesis exhibit significant toxicity, so that high dose cannot be used in either systemic or topical administration.
In addition, exogenous proteins with large molecular weight are also sensitive foreign substances which may cause immune damages to eye tissues such as uveal.
However, due to their relative large molecular weight and complicated spatial conformation, these inhibitors have disadvantages in preparation such as complicated recombinant expression and purification processes, residual endotoxin and so on.
However, they are expensive, repeated intravitreal administrations are necessary, and certain risks, such as vascular embolization will be caused.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptides inhibiting neovascularization and uses thereof
  • Polypeptides inhibiting neovascularization and uses thereof
  • Polypeptides inhibiting neovascularization and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis, Seperation and Purification of Small Peptide ZY3

[0121]The polypeptides ZY3 represented by SEQ ID NO: 1 were synthesized by using the commercially available SYMPHONY polypeptide synthesizer (12-channel, Protein Technologies. LLC., U.S.). The processes were as follows:

[0122]The reagents were calculated and prepared according to the software (Version. 201) of the polypeptide synthesizer. 2-Chlorotrityl Chloride Resin (Nankai Synthetic Technology Co., Ltd, Tianjin, China) was added into a reaction tubes, DMF (15 ml / g) (Dikma) was added and the tube was oscillated for 30 min. Solvents were suction filtered out through the sintered filter. 3-fold excess mole of Fmoc-L-OH (small peptide ZY3) amino acids (Suzhou Tianma Pharma Group Specialty Chemicals Co., Ltd.) was added and then 10-fold excess mole of DIEA (Sinopharm Shanghai Chemical Reagent Company) was added and finally, DMF was added for dissolution. The mixture was oscillated for 30 min. DMF was removed and 20% piperidine ...

example 2

Identification and Storage of Small Peptides ZY3

[0133]A small amount of small peptides ZY3 was taken for purity identification by HPLC analysis and molecular weight identification by ESI-MS.

[0134]The results showed that the elution peak of ZY3 was at 12.8 min with the purity over 99% (FIG. 1).

[0135]Small peptide ZY3 has 27 amino acids in total with a molecular weight of 3092.55. The small peptides in white powder form were sealed, packaged, and stored at −20° C.

example 3

Effect of Small Peptides ZY3 on Proliferation Activity of HUVECs

[0136]The MTS method was used as follows:

[0137]Primary Human Umbilical Vein Endothelial Cells (HUVECs) (purchased from ScienCell Co.) were inoculated into a 96-well plate with an inoculation concentration of 2×104 / ml. After cells had adhered to the wall, serum-free culture medium ECM was added and the cells were cultivated at 37° C. for 24 hours. Then the serum-free culture medium ECM as negative control, VEGF (100 ng / ml) (purchased from Sigma Co.) as positive control, VEGF (100 ng / well)+small peptide ZY3 in different concentrations as treatment groups were added in each well. After a 24-hour incubation, 20 μl 1 MTS solution (purchased from Promega Corporation) was added in each well. After incubation at 37° C. for 4 hours, the absorbance in each well was measured at 490 nm by using microplate reader (Bio-Rad Co.). The proliferation activity of cells was determined according to OD490. Finally, SPSS11.0.1 was used for st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
body weightaaaaaaaaaa
body weightaaaaaaaaaa
Login to view more

Abstract

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

Description

TECHNICAL FIELD[0001]The present invention relates to biomedicine. In particular, the present invention relates to a novel small peptide inhibiting angiogenesis, and said small peptide is a polypeptide derived from Placenta Growth Factor (PLGF). The present invention also relates to a method for preparing the polypeptide, uses thereof, and a pharmaceutical composition comprising the polypeptide.TECHNICAL BACKGROUND[0002]Angiogenesis involves extremely complicated courses including expansion of existing vessels, increase in vascular permeability, degradation of perivescular stroma, activation, proliferation and migration of endothelial cells, and formation of new capillary-like lumina.[0003]About ⅔ of diseases causing blindness are associated with pathological angiogenesis in eyes, for example, corneal angiogenesis induced by simplex herpetic stromal keratitis, choroidal angiogenesis in age-related macular degeneration, and retinal angiogenesis in diabetic retinopathy or retinopathy ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/47
CPCC07K14/4703C07K14/515A61K38/1891A61K9/0048A61K38/1866A61P1/00A61P1/04A61P15/08A61P17/00A61P17/06A61P19/02A61P27/02A61P29/00A61P35/00A61P7/02A61P9/00A61P9/10
Inventor XU, XUNZHENG, YING
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap